Tysabri Progressive Multifocal Leukoencephalopathy Attorney: Statute of Limitations for Tysabri in Ohio

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Specialized Risk Awareness

For decades, public health communication has centered on broad, accessible guidance regarding general wellness and the management of common medical conditions. This foundational approach has served to educate diverse populations on preventive care, symptom recognition, and the importance of informed consent in treatment decisions. Within this legacy framework, the emphasis has been on empowering individuals to navigate routine healthcare interactions with confidence and awareness. As medical science advances, however, the scope of health information must expand to address the complexities of specialized therapies and their potential long-term implications. One such area involves the use of biologic medications for chronic conditions, where treatment benefits must be carefully weighed against possible adverse outcomes. In particular, exposure to certain immunomodulatory agents has been associated with an elevated risk of opportunistic infections, including progressive multifocal leukoencephalopathy (PML)—a serious neurological condition. This shift from general health literacy to specific risk awareness becomes especially critical when considering occupational and environmental contexts. For individuals who have been prescribed such therapies, understanding the timeline for legal recourse—such as the statute of limitations for filing claims in Ohio—is an essential component of post-exposure management. The transition from broad health education to targeted legal and medical vigilance reflects a necessary evolution in how we communicate complex risk scenarios to affected populations.

Medical Background and Risk Factors for Tysabri-Associated PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Ohio who have developed PML after Tysabri treatment, understanding the medical evidence and legal considerations—including the statute of limitations—is critical. PML is an opportunistic viral infection of the brain caused by the JC virus that typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The FDA-approved prescribing information for Tysabri includes a boxed warning stating that the drug increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy, and healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation, Diagnosis, and Mechanistic Pathways

PML presents with a range of neurological deficits that can include progressive weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis typically involves brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The clinical course is often rapid and devastating, with most patients experiencing severe disability or death. The FDA Adverse Event Reporting System (FAERS) data for Tysabri lists fatigue, multiple sclerosis relapse, headache, gait disturbance, and balance disorder among the most frequently reported adverse events (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not specifically isolate PML, they reflect the broad spectrum of neurological symptoms that may overlap with or mask early PML. Tysabri is a monoclonal antibody that binds to alpha-4 integrin, blocking lymphocyte adhesion and migration into the central nervous system. This mechanism reduces inflammatory activity in multiple sclerosis but also impairs immune surveillance against JC virus. Under normal conditions, JC virus is controlled by a competent immune system. By preventing immune cells from entering the brain, Tysabri creates an environment where JC virus can reactivate and cause PML. The risk increases with duration of therapy, particularly beyond two years, and is higher in patients who have received prior immunosuppressants or who are anti-JCV antibody positive (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Adequacy of Warnings and Legal Considerations for Ohio Patients

The boxed warning on Tysabri clearly states the increased risk of PML and identifies the three known risk factors. The drug is only available through a restricted distribution program called the TOUCH Prescribing Program, which is designed to ensure that patients are informed of the risks and that monitoring occurs (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether these warnings were sufficient to allow patients and physicians to make fully informed decisions, particularly in cases where PML developed despite adherence to monitoring protocols. The adequacy of warnings is a central issue in legal claims, as it relates to whether the manufacturer fulfilled its duty to provide reasonable and timely information about known risks. For patients in Ohio who have developed PML after Tysabri treatment, legal action may be pursued under product liability theories, including failure to warn, defective design, or negligence. A critical threshold issue is the statute of limitations, which in Ohio is generally two years from the date the injury was discovered or should have been discovered. This means that the clock starts ticking when the patient or a reasonable person in their position would have become aware of the link between Tysabri and their PML. Given that PML symptoms can initially mimic multiple sclerosis relapse, the date of discovery may be delayed until a definitive diagnosis is made. Patients should consult with an attorney experienced in pharmaceutical litigation to determine whether their claim falls within the statutory window.

Timeline Between Exposure and Documented Harm

The latency period between starting Tysabri and developing PML can vary widely. The risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Some cases have been reported after only a few doses, while others occur after several years of therapy. This variable timeline complicates the legal analysis, as the statute of limitations may begin at different points depending on when symptoms first appeared and when PML was diagnosed. Medical records documenting the onset of neurological symptoms, MRI findings, and JC virus testing are essential for establishing the timeline. Tysabri carries a known risk of PML, a devastating brain infection that often leads to death or severe disability. The FDA-approved labeling identifies specific risk factors and mandates monitoring, but questions about warning adequacy persist. For Ohio patients affected by PML, the statute of limitations is a critical legal consideration that requires prompt evaluation by a qualified attorney. The medical evidence underscores the importance of early recognition and immediate discontinuation of Tysabri at the first sign of PML, but for those already harmed, legal recourse may be available.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Ohio?

In Ohio, the statute of limitations for product liability claims, including those related to Tysabri and PML, is generally two years from the date the injury was discovered or should have been discovered. This means the clock starts when the patient or a reasonable person would have become aware of the link between Tysabri and their PML. Because PML symptoms can mimic multiple sclerosis relapse, the discovery date may be delayed until a definitive diagnosis is made. It is crucial to consult an attorney promptly to evaluate whether your claim falls within this window.

What are the risk factors for developing PML from Tysabri?

The FDA-approved prescribing information identifies three specific risk factors for PML in patients taking Tysabri: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first such sign.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.